The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis
The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is ant...
Saved in:
Published in | Doklady. Biochemistry and biophysics Vol. 517; no. 1; pp. 140 - 147 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Moscow
Pleiades Publishing
01.08.2024
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!